Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

INTRODUCTION: The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inhibitor, in active RA by analyzing secr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Rheumatol Ther
Main Authors: Tarrant, Jacqueline M., Galien, René, Li, Wanying, Goyal, Lovely, Pan, Yang, Hawtin, Rachael, Zhang, Wangshu, Van der Aa, Annegret, Taylor, Peter C.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2020
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021851/
https://ncbi.nlm.nih.gov/pubmed/31912462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00192-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares